Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Slides:



Advertisements
Similar presentations
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Advertisements

The prevalence of “risky behaviour” in adults with cystic fibrosis
Sweat conductivity: An accurate diagnostic test for cystic fibrosis?
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 
Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H
Scott D. Sagel, Marci K. Sontag, Meg M
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis  Marco Zampoli, Komala Pillay, Henri Carrara,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
John Widger, Sarath Ranganathan, Philip J. Robinson 
The ease of breathing test tracks clinical changes in cystic fibrosis
Controlled clinical trials in cystic fibrosis — are we doing better?
Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state  Bradley.
Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar 
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Cystic fibrosis mortality trend in Italy from 1970 to 2011
Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial  S.K. Kabra, R. Pawaiya, Rakesh Lodha,
Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis  Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,
Amyloidosis in cystic fibrosis: A case series
Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous ΔF508 controls  Jonathan McCormick, Simon A. Ogston,
Pulmonary nocardiosis in cystic fibrosis
A.H. Gifford  Journal of Cystic Fibrosis 
Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects  Warren Lenney, Frank Edenborough,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Predicting hypoxia in cystic fibrosis patients during exposure to high altitudes  Wolfgang Kamin, Birthe Fleck, Dirk-Mathias Rose, Oliver Thews, Wolfgang.
Inhalation solutions — Which ones may be mixed
Physiologic endpoints for clinical studies for cystic fibrosis
Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis  D.W. Reid, R. Latham, I.L.
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?
Depression and anxiety in adolescents and adults with cystic fibrosis in the UK: A cross- sectional study  Alistair J.A. Duff, Janice Abbott, Carolyn Cowperthwaite,
Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy  G. Fitch, K. Williams,
Cytokine gene polymorphisms and severity of CF lung disease
Narelle S. Cox, Jennifer Follett, Karen O. McKay 
Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients  E.B. Wilms, D.J. Touw, H.G.M. Heijerman 
Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.
Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale 
Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis  Joseph M. Collaco, Karen S. Raraigh, Lawrence.
Higher risk of hospitalization among females with cystic fibrosis
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal 
Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis  M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,
Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS  Dorota Sands, Ewa Sapiejka, Grzegorz.
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
H. White, A.M. Morton, S.P. Conway, D.G. Peckham 
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher 
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
CFTR modulators and pregnancy: Our work has only just begun
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis  Ahmet Z. Uluer, David A. Waltz, Leslie.
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial  Michael W. Konstan, Patrick A. Flume, Matthias.
Cystic fibrosis and pregnancy in the modern era: A case control study
R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P
Presentation transcript:

Safety assessment of inhaled xylitol in subjects with cystic fibrosis Lakshmi Durairaj, Janice Launspach, Janet L. Watt, Zeinab Mohamad, Joel Kline, Joseph Zabner  Journal of Cystic Fibrosis  Volume 6, Issue 1, Pages 31-34 (January 2007) DOI: 10.1016/j.jcf.2006.05.002 Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Effect of exposure to nebulized saline and xylitol on FEV1 in 6 subjects with cystic fibrosis. Journal of Cystic Fibrosis 2007 6, 31-34DOI: (10.1016/j.jcf.2006.05.002) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Sputum IL-8 levels after saline and xylitol exposure in 5 subjects with cystic fibrosis (grey circles). Solid squares represent the mean Il-8 values. Journal of Cystic Fibrosis 2007 6, 31-34DOI: (10.1016/j.jcf.2006.05.002) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions